Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
| AstraZeneca | INDUSTRY |
| US Department of Veterans Affairs | FED |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether quetiapine fumarate extended release is effective in the treatment of alcohol dependence in very heavy drinkers.
This study will investigate quetiapine fumarate XR (SEROQUEL XR®), a dibenzothiazepine derivative, as a potential medication for treating alcohol dependence. The immediate release form of quetiapine fumarate, SEROQUEL XR®, is approved by the FDA for treatment of schizophrenia and acute manic episodes associated with bipolar disorder. The extended release formulation (SEROQUEL XR®) is also approved by the FDA and is undergoing clinical investigation for the treatment of major depressive disorders, schizophrenia, generalized anxiety disorder, and alcohol dependence.
Treatment with other atypical antipsychotics such as clozapine and olanzapine has resulted in decreases in alcohol use in alcohol dependent patients with and without comorbid psychiatric diagnoses. Quetiapine, like clozapine, appears to have efficacy in reducing drug and alcohol use among alcoholics and drug dependent patients with co-morbid psychiatric illness.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Quetiapine fumarate plus medical management |
|
| 2 | Placebo Comparator | Medical management plus placebo comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quetiapine fumarate | Drug | Quetiapine fumarate- taken daily, for 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent Heavy Drinking Days | A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period. | Weeks 3 - 11 |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Days Abstinent | Timeline Follow-back drinking data is used to calculate the % of days abstinent per week during Weeks 3-11 | Weeks 3-11 |
| Drinks Per Drinking Day | Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per drinking day |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Please contact site for additional information.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Raye Z. Litten, PhD | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Study Director |
| Margaret E. Mattson, PhD | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Principal Investigator |
| Joanne Fertig, PhD | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boston University School of Medicine, Psychiatry Clinical Studies Unit | Boston | Massachusetts | 02118 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21950727 | Result | Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R; NCIG 001 Study Group. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Mar;36(3):406-16. doi: 10.1111/j.1530-0277.2011.01649.x. Epub 2011 Sep 26. | |
| 32963470 |
Not provided
Not provided
218 comprises the Modified Intent To Treat group (MITT)
Interested candidates responded by telephone to advertisements at 5 academic centers in the United States between December 2007 and May 2009.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Quetiapine Fumerate Plus Medical Management | Quetiapine fumarate - target dose 400mg/day plus medical management |
| FG001 | Sugar Pill Plus Medical Management | Medical management plus placebo comparator |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Placebo |
|
| Study Weeks 3-11 |
| Drinks Per Day | Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per day | Study Weeks 3-11 |
| Percent Very Heavy Drinking Day | Timeline Follow Back data used to calculate the % of very heavy drinking days per week. Heavy drinking is 10+ drinks per day for females and 12+ drinks per day for males | Study Weeks 3-11 |
| Percent Subjects Abstinent | Timeline Follow Back data used to calculate the % of subjects that maintained abstinence weeks 3-11. | Study Weeks 3-11 |
| Percent Subjects With no Heavy Drinking Day | Timeline Follow Back data used to calculate the % of subjects that didn't have a heavy drinking day during study weeks 3-11. | Study Weeks 3-11 |
| Drinking Consequences Score | Drinkers Inventory of Consequences (DrInC) - Alcohol-related problems are determined using the DrInC (Miller et al., 1995). The DrInC is a self-administered 50-item questionnaire designed to measure adverse consequences of alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. Each scale provides a lifetime and past 3-month measure of adverse consequences, and scales can be combined to assess total adverse consequences. We used a modified version of the DrInC that just included the 45-items that summed the Interpersonal, Physical, Social, and Impulsivity items. This total score (min=0, max=135) was analyzed in this study with high scores indicative of more alcohol-related consequences (a poor outcome for a given study participant). The DrInC was assessed at study weeks 6 and 12. Analyses averaged across these weeks. | Weeks 6 & 12 |
| Penn Alcohol Craving Score (PACS_ | The Penn Alcohol Craving Scale (PACS) is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week (Flannery et al., 1999). The summed total score of the 5 items was used in the analysis (min=0, max=30) with higher scores indicative of higher craving for alcohol (a poor outcome). Based on clinical study results, the PACS has been shown to be a reliable and valid measure of alcohol craving and can predict subjects at risk for subsequent relapse. The PACS was assessed at study weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks. | Weeks 4, 6, 8, 10, and 12 |
| Montgomery-Asberg Depression Rating Scale (MADRS) | The MADRS is an observer rating scale that has proven to be an efficient and practical measure of depression (Montgomery and Asberg, 1979). The scale was constructed to be sensitive to changes in treatment effects. Its capacity to differentiate between responders and non-responders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression, another established measure of depressive symptomatology, but the MADRS has greater sensitivity to change during the course of a depressive phase. It has exhibited high inter-rater reliability and appears to be oriented more towards psychic as opposed to somatic aspects of depression. The MADRS is the sum of the 10-item in a checklist where items are rated on a scale of 0 to 6 with anchors at 2-point intervals. Scores range from 0 to 60. Higher scores are indicative of greater depressive symptoms (a poor outcome). The MADRS was assessed at weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks. | Weeks 3-11 |
| Hamilton Anxiety Scale (HAM-A) | The Hamilton Anxiety Scale consists of 14 items, each defined by a series of symptoms. Similar to the HAM-D, each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) (Guy, 1976). A total score is derived from the summed items (min=0, max=56) with higher scores indicative of greater anxiety (a poor outcome). The HAM-A was assessed at study weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks. | Weeks 4, 6, 8, 10, and 12 |
| Pittsburgh Sleep Quality Score | The PSQI is a 19-item questionnaire assessing the subject's overall sleep experience in the past 30 days (Buysse et al-1989). The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations. Range is (0-21); >6 indicative of "poor" sleep quality. The PSQI was assessed at study weeks 4,8, and 12. Analyses averaged across these weeks. | Weeks 4, 8, 12 |
| Quality of Life SF - 12 - Mental Aggregate Score | The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy. We calculated the physical and mental component summary scores which were both converted to T-scores (min=0, max=100) normed to the general population such that a T=50 is the average score in the general population. Higher scores are indicative of better health status. | Week 12 |
| Quality of Life SF-12 - Physical Aggregate Score | The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy. We calculated the physical and mental component summary scores which were both converted to T-scores (min=0, max=100) normed to the general population such that a T=50 is the average score in the general population. Higher scores are indicative of better health status. | Week 12 |
| Dartmouth Medical School, Dept. of Psychiatry |
| Lebanon |
| New Hampshire |
| 03755 |
| United States |
| University of Pennsylvania, Treatment Research Center | Philadelphia | Pennsylvania | 19104 | United States |
| Brown University Center for Alcohol and Addiction Studies | Providence | Rhode Island | 12906 | United States |
| White River Junction VA Medical Center | White River Junction | Vermont | 05009 | United States |
| University of Virginia, Dept. of Psychiatric Medicine | Charlottesville | Virginia | 22908 | United States |
| University of Virginia | Richmond | Virginia | 23294 | United States |
| Derived |
| Vatsalya V, Kong M, Marsano LM, Kurlawala Z, Chandras KV, Schwandt ML, Ramchandani VA, McClain CJ. Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients. Subst Abuse. 2020 Sep 9;14:1178221820955185. doi: 10.1177/1178221820955185. eCollection 2020. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Quetiapine Fumerate Plus Medical Management | Quetiapine fumarate - target dose 400mg/day plus medical management |
| BG001 | Sugar Pill Plus Medical Management | Medical management plus placebo comparator |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent Heavy Drinking Days | A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period. | Intention to Treat | Posted | Least Squares Mean | Standard Error | percentage of heavy drinking days | Weeks 3 - 11 |
|
|
| ||||||||||||||||||||||||||||
| Secondary | Percent Days Abstinent | Timeline Follow-back drinking data is used to calculate the % of days abstinent per week during Weeks 3-11 | Posted | Least Squares Mean | Standard Error | percentage of days abstinent | Weeks 3-11 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Drinks Per Drinking Day | Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per drinking day | Posted | Least Squares Mean | Standard Error | drinks per drinking day | Study Weeks 3-11 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Drinks Per Day | Timeline Follow Back daily drinking data used to calculate the weekly mean drinks per day | Posted | Least Squares Mean | Standard Error | drinks per day | Study Weeks 3-11 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Percent Very Heavy Drinking Day | Timeline Follow Back data used to calculate the % of very heavy drinking days per week. Heavy drinking is 10+ drinks per day for females and 12+ drinks per day for males | Posted | Least Squares Mean | Standard Error | percentage heavy drinking days | Study Weeks 3-11 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Percent Subjects Abstinent | Timeline Follow Back data used to calculate the % of subjects that maintained abstinence weeks 3-11. | Posted | Count of Participants | Participants | Study Weeks 3-11 |
|
| |||||||||||||||||||||||||||||||
| Secondary | Percent Subjects With no Heavy Drinking Day | Timeline Follow Back data used to calculate the % of subjects that didn't have a heavy drinking day during study weeks 3-11. | Posted | Count of Participants | Participants | Study Weeks 3-11 |
|
| |||||||||||||||||||||||||||||||
| Secondary | Drinking Consequences Score | Drinkers Inventory of Consequences (DrInC) - Alcohol-related problems are determined using the DrInC (Miller et al., 1995). The DrInC is a self-administered 50-item questionnaire designed to measure adverse consequences of alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. Each scale provides a lifetime and past 3-month measure of adverse consequences, and scales can be combined to assess total adverse consequences. We used a modified version of the DrInC that just included the 45-items that summed the Interpersonal, Physical, Social, and Impulsivity items. This total score (min=0, max=135) was analyzed in this study with high scores indicative of more alcohol-related consequences (a poor outcome for a given study participant). The DrInC was assessed at study weeks 6 and 12. Analyses averaged across these weeks. | Posted | Least Squares Mean | Standard Error | score on a scale | Weeks 6 & 12 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Penn Alcohol Craving Score (PACS_ | The Penn Alcohol Craving Scale (PACS) is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week (Flannery et al., 1999). The summed total score of the 5 items was used in the analysis (min=0, max=30) with higher scores indicative of higher craving for alcohol (a poor outcome). Based on clinical study results, the PACS has been shown to be a reliable and valid measure of alcohol craving and can predict subjects at risk for subsequent relapse. The PACS was assessed at study weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks. | Posted | Mean | Standard Error | score on a scale | Weeks 4, 6, 8, 10, and 12 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Montgomery-Asberg Depression Rating Scale (MADRS) | The MADRS is an observer rating scale that has proven to be an efficient and practical measure of depression (Montgomery and Asberg, 1979). The scale was constructed to be sensitive to changes in treatment effects. Its capacity to differentiate between responders and non-responders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression, another established measure of depressive symptomatology, but the MADRS has greater sensitivity to change during the course of a depressive phase. It has exhibited high inter-rater reliability and appears to be oriented more towards psychic as opposed to somatic aspects of depression. The MADRS is the sum of the 10-item in a checklist where items are rated on a scale of 0 to 6 with anchors at 2-point intervals. Scores range from 0 to 60. Higher scores are indicative of greater depressive symptoms (a poor outcome). The MADRS was assessed at weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks. | Posted | Least Squares Mean | Standard Error | score on a scale | Weeks 3-11 |
| |||||||||||||||||||||||||||||||
| Secondary | Hamilton Anxiety Scale (HAM-A) | The Hamilton Anxiety Scale consists of 14 items, each defined by a series of symptoms. Similar to the HAM-D, each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) (Guy, 1976). A total score is derived from the summed items (min=0, max=56) with higher scores indicative of greater anxiety (a poor outcome). The HAM-A was assessed at study weeks 4, 6, 8, 10, and 12. Analyses averaged across these weeks. | Posted | Least Squares Mean | Standard Error | score on a scale | Weeks 4, 6, 8, 10, and 12 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Pittsburgh Sleep Quality Score | The PSQI is a 19-item questionnaire assessing the subject's overall sleep experience in the past 30 days (Buysse et al-1989). The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations. Range is (0-21); >6 indicative of "poor" sleep quality. The PSQI was assessed at study weeks 4,8, and 12. Analyses averaged across these weeks. | Posted | Least Squares Mean | Standard Error | score | Weeks 4, 8, 12 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Quality of Life SF - 12 - Mental Aggregate Score | The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy. We calculated the physical and mental component summary scores which were both converted to T-scores (min=0, max=100) normed to the general population such that a T=50 is the average score in the general population. Higher scores are indicative of better health status. | Posted | Least Squares Mean | Standard Error | score on a scale | Week 12 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Quality of Life SF-12 - Physical Aggregate Score | The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy. We calculated the physical and mental component summary scores which were both converted to T-scores (min=0, max=100) normed to the general population such that a T=50 is the average score in the general population. Higher scores are indicative of better health status. | mITT | Posted | Least Squares Mean | Standard Error | score on a scale | Week 12 |
|
|
Not provided
Systematic assessment at each clinic visit and telephone contact in response to the question "How have you been feeling since the last time we spoke?"
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Quetiapine Fumerate Plus Medical Management | Quetiapine fumarate - target dose 400mg/day plus medical management | 6 | 105 | 105 | 105 | ||
| EG001 | Sugar Pill Plus Medical Management | Medical management plus placebo comparator | 5 | 113 | 110 | 113 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Alcohol Detoxification | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Automobile Accident | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| Behavioral Disturbance while intoxicated | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Pre-ventricular contractions | Cardiac disorders | MedDRA | Systematic Assessment |
| |
| Ruptured Spleen | Blood and lymphatic system disorders | MedDRA | Systematic Assessment |
| |
| Suicidal Ideation | Psychiatric disorders | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dizziness | Nervous system disorders | Systematic Assessment |
| ||
| Dry Mouth | Gastrointestinal disorders | Systematic Assessment |
| ||
| Dyspepsia | Gastrointestinal disorders | Systematic Assessment |
| ||
| Increased Appetite | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Sedation | Nervous system disorders | Systematic Assessment |
| ||
| Somnelence | Nervous system disorders | Systematic Assessment |
| ||
| Headache | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Tremor | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Depressed Mood | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Abnormal Dreams | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Agitation | Psychiatric disorders | MedDRA | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA | Systematic Assessment |
| |
| Feeling Abnormal | General disorders | MedDRA | Systematic Assessment |
| |
| Irritability | General disorders | MedDRA | Systematic Assessment |
| |
| Pain | General disorders | MedDRA | Systematic Assessment |
| |
| Nasal Congestion | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Oropharynageal Pain | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Weight Increased | Investigations | MedDRA | Systematic Assessment |
| |
| Blood Glucose Increased | Investigations | MedDRA | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Mylagia | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Upper Respiratory Tract Infection | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Raye Litten | NIAAA | 301-443-0636 |
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069348 | Quetiapine Fumarate |
| ID | Term |
|---|---|
| D003987 | Dibenzothiazepines |
| D013841 | Thiazepines |
| D013846 | Thiepins |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| >=65 years |
|
| Male |
|
|
|
|
|
|
|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|